Phase 2 clinical trial of attenuated Salmonella enterica serovar typhi oral live vector vaccine CVD 908-htrA in U.S. volunteers

Infection and Immunity

Volumn 68, Issue 3, 2000, Pages 1196-1201

  Tacket, Carol O ^a   Sztein, Marcelo B ^a   Wasserman, Steven S ^a   Losonsky, Genevieve ^a   Kotloff, Karen L ^a   Wyant, Timothy L ^a   Nataro, James P ^a   Edelman, Robert ^a   Perry, Judith ^b   Bedford, Philip ^c   Brown, David ^d   Chatfield, Stephen ^e,g   Dougan, Gordon ^f   Levine, Myron M ^a  

^a University of Maryland School of Medicine Center for Vaccine Development   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c Peptide Therapeutics   (United Kingdom)

^d Evans Medical Ltd   (United Kingdom)

^e Medeva Group Research   (United Kingdom)

^f IMPERIAL COLLEGE LONDON   (United Kingdom)

^g Microscience Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LIVE VACCINE; TYPHOID VACCINE;

ADULT; ANOREXIA; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; BLOOD CULTURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; MALAISE; MALE; MUSCLE CRAMP; NORMAL HUMAN; PRIORITY JOURNAL; TYPHOID FEVER;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; BACTERIAL VACCINES; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; GENETIC VECTORS; HEAT-SHOCK PROTEINS; HUMANS; INTERFERON TYPE II; LYMPHOCYTE ACTIVATION; MALE; PERIPLASMIC PROTEINS; SALMONELLA TYPHI; SERINE ENDOPEPTIDASES; VACCINES, INACTIVATED;

EID: 0033964153     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.68.3.1196-1201.2000     Document Type: Article

References (26)

1. Acharya, I. L., C. U. Lowe, R. Thapa, V. L. Gurubacharya, M. B. Shrestha, M. Cadoz, D. Schulz, J. Armand, D. A. Bryla, B. Trollfors, T. Cramton, R. Schneerson, and J. B. Jobbins. 1987. Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi. N. Engl. J. Med. 317: 1101-1104.
2. Barry, E. M., O. Gomez-Duarte, S. Chatfield, R. Rappuoli, M. Pizza, G. Losonsky, J. Galen, and M. M. Levine. 19996. Expression and immunogenicity of pertussis toxin S1 subunit-tetanus toxin fragment C fusions in Salmonella typhi vaccine strain CVD 908. Infect. Immun. 64:4172-4181.
3. Black, R., M. M. Levine, C. Young, J. Rooney, S. Levine, M. L. Clements, S. O'Donnell, T. Hughes, R. Germanier, and Chilean Typhoid Committee. 1983. Immunogenicity of Ty21a attenuated Salmonella typhi given with sodium bicarbonate or in enteric-coated capsules. Dev. Biol. Stand. 53:9-14.
4. Brown, A., E. C. Hormaeche, R. Demarco de Hormaeche, M. Winther, G. Dougan, D. J. Maskell, and B. A. D. Stocker. 1987. An attenuated aroA Salmonella typhimurium vaccine elicits humoral and cellular immunity to cloned β-galactosidose in mice. J. Infect. Dis. 155:86-92.
5. Chatfield, S. N., K. Strahan, D. Pickard, I. G. Charles, C. E. Hormaeche, and G. Dougan. 1992. Evaluation of Salmonella typhimurium strains harbouring defined mutations in htrA and aroA in the murine salmonellosis model. Microb. Pathog. 12:145-151.
6. Galen, J. E., O. G. Gomez-Duarte, G. A. Losonsky, J. L. Halpern, C. S. Lauderbaugh, S. Kaintuck, M. K. Reymann, and M. M. Levine. 1997. A murine model of intranasal immunization to assess the immunogenicity of attenuated Salmonella yphi live vector vaccines in stimulating serum antibody responses to expressed foreign antigens. Vaccine 15:700-708.
7. Germanier, R., and E. Fürer. 1975. Isolation and characterization of gal E mutant Ty21a of Salmonella typhi: a candidate strain for a live oral typhoid vaccine. J. Infect. Dis. 141:553-558.
8. Girón, J. A., J.-G. Xu, R. González, D. Hone, J. B. Kaper, and M. M. Levine. 1995. Simultaneous expression of CFA/1 and CS3 colonization factor antigens of enterotoxigenic Escherichia coli by ΔaroC, ΔaroD Salmonella typhi vaccine strain CVD 908. Vaccine 13:939-946.
9. González, R., D. Hone, F. R. Noriega, C. O. Tacket, J. R. Davis, G. Losonsky, J. P. Nataro, S. Hoffman, A. Malik, E. Nardin, M. B. Sztein, D. G. Heppner, T. R. Fouts, A. Isibasi, and M. M. Levine. 1994. Salmonella typhi vaccine strain CVD 908 expressing the circumsporozoitc protein of Plasmodium falciparum: strain construction and safety and immunogenicity in humans. J. Infect. Dis. 169:927-931.
10. Hoiseth, S. K., and B. A. D. Stocker. 1981. Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines. Nature 291: 238-239.
11. Johnson, K., I. Charles, G. Dougan, D. Pickard, P. O'Gaora, G. Costa, T. Ali, I. Miller, and C. Hormaeche. 1991. The role of a stress-response protein in Salmonella typhimurium virulence. Mol. Microhiol. 5:401-407.
12. Killar, L. M., and T. K. Eisenstein. 1985. Immunity to Salmonella typhimurium infection in C3H/HeJ and C3H/HeNCrlBR mice: studies with an aromatic-dependent live S. typhimurium strain as a vaccine. Infect. Immun. 47:605-612.
13. Klugman, K. P., I. T. Gilbertson, H. J. Koornof, J. B. Robbins, R. Schneerson, D. Schulz, M. Cadoz, J. Armand, and Vaccination Advisory Committee. 1987. Protective activity of Vi capsular polysaccharide vaccine against typhoid fever. Lancet ii:1165-1169.
14. Levine, M., D. Herrington, J. Murphy, J. Morris, G. Losonsky, B. Tall, A. Lindberg, S. Svenson, S. Baqar, M. Edwards, and B. Stocker. 1987. Safety, infectivity, immunogenicity, and in vivo stability of two attenuated auxotrophic mutant strains of Salmonella typhi, 541Ty and 543Ty, as live oral vaccines in humans. J. Clin. Investig. 79:888-902.
15. Levine, M. M., H. L. DuPont, R. B. Hornick, M. J. Snyder, W. Woodward, R. H. Gilman, and J. P. Libonati. 1976. Attenuated streptomycin-dependent Salmonella lyphi oral vaccine: potential deleterious effects of lyophilization. J. Infect. Dis. 133:424-428.
16. Levine, M. M., C. Ferreccio, R. E. Black, C. O. Tacket, and R. Germanier. 1989. Progress in vaccines against typhoid fever. Rev. Infect. Dis. 2(Suppl. 3): S552-S567.
17. Lowe, D. C., T. C. Savidge, D. Pickard, L. Eckmann, M. F. Kagnoff, G. Dougan, and S. N. Chatfield. 1999. Characterization of candidate live oral Salmonella typhi vaccine strains harboring defined mutations in aroA, aroC, and htrA. Infect. Immun. 67:700-707.
18. Pasetti, M. F., R. J. Anderson, F. R. Noriega, M. M. Levine, and M. B. Sztein. 1999. Attenuated ΔguaBA Salmonella typhi vaccine strain CVD 915 as a live vector utilizing prokaryotic or eukaryotic expression systems to deliver foreign antigens and elicit immune responses. Clin. Immunol. 92:76-89.
19. Smith, B. P., M. Reina-Guerra, S. K. Hoiseth, B. A. D. Stocker, F. Habasha, E. Johnson, and F. Merritt. 1984. Aromatic-dependent Salmonella typhimurium as modified live vaccines for calves. Am. J. Vet. Res. 45:59-66.
20. Sztein, M. B., M. K. Tanner, Y. Polotsky, J. M. Orenstein, and M. M. Levine. 1995. Cytotoxic T lymphocytes after oral immunization with attenuated vaccine strains of Salmonella typhi in humans. J. Immunol. 155:3987-3993.
21. Sztein, M. B., S. S. Wasserman, C. O. Tacket, R. Edelman, D. Hone, A. A. Lindberg, and M. M. Levine. 1994. Cytokine production patterns and lymphoproliferative responses in volunteers orally immunized with attenuated vaccine strains of Salmonella typhi. J. Infect. Dis. 170:1508-1517.
22. Tacket, C. O., B. Forrest, R. Morona, S. R. Attridge, J. LaBrooy, B. D. Tall, M. Reymann, D. Rowley, and M. M. Levine. 1990. Safety, immunogenicity, and efficacy against cholera challenge in humans of a typhoid-cholera hybrid vaccine derived from Salmonella typhi Ty21a. Infect. Immun. 58:1620-1627.
23. Tacket, C. O., D. M. Hone, R. Curtiss III, S. M. Kelly, G. Losonsky, L. Guers, A. Harris, R. Edelman, and M. M. Levine. 1992. Comparison of the safety and immunogenicity of ΔaroC aroD and Δcya Δcrp Salmonella typhi strains in adult volunteers. Infect. Immun. 60:536-541.
24. Tacket, C. O., D. M. Hone, G. A. Losonsky, L. Guers, R. Edelman, and M. M. Levine. 1992. Clinical acceptability and immunogenicity of CVD 908 Salmonella typhi vaccine strain. Vaccine 10:443-446.
25. Tacket, C. O., S. M. Kelly, F. Schodel, G. Losonsky, J. P. Nataro, R. Edelman, M. M. Levine, and R. Curtiss III. 1997. Safety and immunogenicity in humans of an attenuated Salmonella typhi vaccine vector strain expressing plasmid-encoded hepatitis B antigens stabilized by the Asd-balanced lethal vector system. Infect. Immun. 65:3381-3385.
26. Tacket, C. O., M. B. Sztein, G. A. Losonsky, S. S. Wasserman, J. P. Nataro, R. Edelman, D. Pickard, G. Dougan, S. N. Chatfield, and M. M. Levine. 1997. Safety of live oral Salmonella typhi vaccine strains with deletions in htrA and aroC aroD and immune response in humans. Infect. Immun. 65:452-456.